Platform Application for Autoimmune Diseases
Autoimmune Diseases
Pre-clinical/ResearchActive
Key Facts
About ALTUCELL
Altucell is a preclinical-stage biotech company pioneering a microencapsulation platform for cell and regenerative therapies targeting major chronic diseases. Its initial focus appears to be on diabetes, with potential applications in autoimmune and neurodegenerative conditions, aiming to provide long-term therapeutic solutions without chronic immunosuppression. The company is privately held and likely pre-revenue, advancing its research through partnerships and its scientific advisory network. Its value proposition centers on a potentially broadly applicable encapsulation technology designed to protect transplanted cells from immune rejection.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira (Adalimumab) Biosimilar | NeuClone | Early Preclinical |
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Gavocabtagene autoleucel | astellas | Phase 1/2 |
| TYK-101 | TYK Medicines | Phase 1 |
| HCB206 | HanchorBio | Preclinical |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |